NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it is expected to join the Russell Microcap Index as part of the first semi-annual 2026 Russell indexes reconstitution, according to preliminary index addition lists published by FTSE Russell on May 22, May 29, and June 5, 2026. The newly reconstituted Russell indexes take effect after the US market close on Friday, June 26, 2026.
“We are pleased that NeuroOne is expected to be added to the Russell Microcap Index,” said Dave Rosa, Chief Executive Officer of NeuroOne. “We believe our inclusion reflects the commercial momentum we have built across our portfolio of FDA-cleared electrode and ablation technologies, and the increasing recognition of NeuroOne within the investment community. We expect membership in the index to expand our visibility among institutional investors and broaden our shareholder base as we continue our mission of transforming the treatment of neurological disorders.”
This development is significant for NeuroOne, a medical technology company focused on improving surgical care for neurological disorders. The company markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
Inclusion in the Russell Microcap Index is expected to enhance NeuroOne's profile among institutional investors, many of which use Russell indexes as benchmarks for investment strategies. This could lead to increased demand for NMTC shares as index funds and ETFs that track the Russell Microcap Index automatically add the stock. For leaders in business and technology, this move signals that NeuroOne is gaining traction in the competitive medical device space, particularly in the growing field of neuromodulation and minimally invasive neurosurgery.
The transition from an annual to a semi-annual reconstitution schedule for Russell US Indexes, announced by FTSE Russell, also provides more frequent opportunities for companies like NeuroOne to gain index membership. This change reflects the evolving dynamics of the public markets and the need for indexes to adapt to the pace of company growth.
For readers, the implications are twofold: First, NeuroOne's inclusion validates its commercial progress and technology adoption, potentially making it a more attractive partner or acquisition target. Second, for investors, the index addition could provide a liquidity event and price appreciation, though forward-looking statements caution about risks such as supply chain disruptions, regulatory changes, and capital requirements. As NeuroOne continues to develop its pipeline, including drug delivery and spinal cord stimulation, its index membership may help fund these initiatives by attracting a broader investor base.
NeuroOne's forward-looking statements emphasize that actual results may differ materially due to factors outside the company's control. The company undertakes no obligation to update these statements. For more information, visit nmtc1.com.
